Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Coya completes enrollment in ALS trial, data due early Q2 2027

Coya completes enrollment in ALS trial, data due early Q2 2027

Coya Therapeutics Inc. (NASDAQ:COYA) has enrolled 120 patients in its Phase 2/3 ALSTARS trial assessing COYA 302 as a treatment for amyotrophic lateral sclerosis (ALS). The trial, which is randomized, multicenter, and double-blind, involves a combination of low-dose IL-2 and CTLA-4 Ig. Participants will be randomized to receive one of two dosing regimens of COYA 302 or a placebo during the first 24 weeks.

Following the initial phase, patients who received COYA 302 will continue treatment for an additional 24 weeks, while those on placebo will be re-randomized to receive one of the two active dosing regimens. The primary endpoint of the study is a change in disease severity measured by the ALS Functional Rating Scale-Revised total score from baseline to week 24 compared to placebo.

Coya Therapeutics partnered with Dr. Reddy’s Laboratories Ltd. for the development and commercialization of COYA 302 in December 2023. The drug has received FDA Fast Track designation for ALS treatment, aiming to expedite its development and regulatory approval for serious conditions with unmet medical needs.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at investing.com →

More in Health & Medicine

More from Monday 5 October →